In this article we will discuss Olaparib (Description-14). So, let’s get started. Carcinogenesis Carcinogenicity studies have not been conducted with Olaparib. Olaparib was clastogenic in an in vitro chromosomal aberration assay in mammalian (CHO) cells and in an in vivo rat bone marrow micronucleus assay. This clastogenicity is consistent with genomic instability resulting from the […]
Category: Oncology
In this article we will discuss Olaparib (Description-13)
In this article, we will discuss Olaparib (Description-12). So, let’s get started. Drug Interactions (3) In vitro studies have shown that olaparib is both an inhibitor and inducer of CYP3A and an inducer of CYP2B6. Olaparib is predicted to be a weak CYP3A inhibitor in humans. In vitro studies also indicated that olaparib is an […]
In this article, we will discuss Olaparib (Description-11). So, let’s get started. Drug Interactions (2) Based on the data from a drug-interaction trial (n=22), the AUC and Cmax of olaparib decreased by 87% and 71%, respectively, when olaparib was administered in combination with rifampicin, a strong CYP3A inducer. Simulations suggested that a moderate CYP3A inducer […]
In this article, we will discuss Olaparib (Description-10). So, let’s get strarted. Drug Interactions Based on the data from a drug-interaction trial (n=57), the AUC and Cmax of olaparib increased by 170% and 42%, respectively, when Olaparib was administered in combination with itraconazole, a strong CYP3A inhibitor. Simulations suggested that a moderate CYP3A inhibitor (fluconazole) […]